cabozantinib

You have access
Second-line Treatment Strategy in Unresectable Hepatocellular Carcinoma After First-line Atezolizumab Plus Bevacizumab
KUNIHIDE MOHRI, HIDENARI NAGAI, TAKAHISA MATSUDA, YOSHINORI IGARASHI and KOJI HIGAI

Anticancer Research September 2024, 44 (9) 3919-3929; DOI: https://doi.org/10.21873/anticanres.17220
You have access
Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma
RYO SATO, YUTO MATSUSHITA, AYANA TAKEMURA, MOMOKO SUGIYAMA, KYOHEI WATANABE, HIROMITSU WATANABE, KEITA TAMURA, DAISUKE MOTOYAMA, MASAO NAGATA, ATSUSHI OTSUKA, HIROSHI FURUSE and HIDEAKI MIYAKE

Anticancer Research February 2024, 44 (2) 781-786; DOI: https://doi.org/10.21873/anticanres.16869
You have access
Antitumor Activity of Cabozantinib in Metastatic Adult Ewing Sarcoma: A Case Report
DENIS SCHALLIER, PIERRE LESFEVRE and HENDRIK EVERAERT

Anticancer Research April 2020, 40 (4) 2265-2269; DOI: https://doi.org/10.21873/anticanres.14190
You have access
Polycystic Liver Disease in a Patient With Metastatic Renal Cell Carcinoma: A Case Report
LUCAS ZARLING, HAMID EMAMEKHOO, GAURI BHUTANI, TIMOTHY ZIEMLEWICZ, KRISTINA A. MATKOWSKYJ and CHRISTOS E. KYRIAKOPOULOS

Anticancer Research March 2020, 40 (3) 1527-1534; DOI: https://doi.org/10.21873/anticanres.14098
You have access
The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In Vitro and In Vivo
MAKIKO NAKATANI, HIDEMICHI WATARI, TAKASHI MITAMURA, LEI WANG, YUTAKA HATANAKA, KANAKO C. HATANAKA, KOHEI HONDA, TOSHIYUKI NOMURA, HIROSHI NISHIHARA, SHINYA TANAKA and NORIAKI SAKURAGI

Anticancer Research November 2017, 37 (11) 6125-6132;

Main menu

User menu

Search

cabozantinib